Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology announces a definitive agreement for Novartis to acquire Pikavation Therapeutics, Inc. (“Pikavation”) and its portfolio of PI3Kα inhibitor programs, including SNV4818. Pikavation is a wholly-owned subsidiary of Synnovation. SNV4818 is a potentially best-in-class pan-mutant selective PI3Kα inhibitor currently in Phase 1/2 clinical trials for the treatment of HR+/HER2- metastatic breast cancer and other solid tumors.
Read the full article: Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program //
Source: https://www.businesswire.com/news/home/20260319220518/en/Novartis-to-Acquire-Synnovation-Therapeutics-Pan-Mutant-Selective-PI3K-Inhibitor-Program